Przeglądanie według Autor "Sundar, Subash"

Aktualnie wyświetlane 1 - 3 z 3

A comparative study on the utility of biomarkers – serum interleukin-13 against serum immunoglobulin E in assessing the severity of asthma
(Rzeszów University Press, 2025-06) Raju, Prasanna; Sundar, Subash; Suresh, Preethi; Thulukanam, Jayaprakash; Srinivasan, Padmanaban
Introduction and aim. Asthma is a complex respiratory condition with fluctuating symptoms, airflow obstruction, bronchial hyperresponsiveness, and inflammation. Interleukin (IL)-13 induces various biological responses, including B-cell immunoglobulin E (IgE), eosinophil chemo-attractants, and mucus-secreting goblet cell maturation. B-cell immunoglobulin E antibodies are essential for the onset and propagation of the inflammatory cascade, triggering the allergic response. The aim was to compare the utility of biomarkers – serum IL-13 against serum IgE in assessing the severity of asthma. Material and methods. A cross-sectional observational study was conducted involving 68 asthmatic children aged 6–12 years and 68 age- and sex-matched healthy controls. Asthma severity was assessed using spirometry and categorized as mild, moderate, or severe based on GINA guidelines. Serum IL-13 and IgE levels were measured using validated using enzyme-linked immunosorbent assay. Results. The study confirmed elevated levels of serum IL-13 and IgE in children with asthma compared to the control group, suggesting their involvement in the development of asthma (p<0.001). The threshold values for identifying the existence of asthma were 1.86 pg/mL for IL-13 and 314 ng/ml for IgE. The IL-13 level could accurately classify asthmatic children as having either moderate or severe asthma, using a cut-off value of ≥2.66 pg/mL, with a statistically significant p=0.001. However, no such results were observed with IgE. Conclusion. Bronchial asthma patients had markedly higher levels of total IgE and IL-13 compared to the healthy controls included in the study. Furthermore, it has been shown that IL-13 plays a role in discerning the extent of asthma severity.
Corrigendum: Interleukin-13 as a potential biomarker in the management of pediatric asthma – a longitudinal study
(Rzeszów University Press, 2025-06) Raju, Prasanna; Sundar, Subash; Suresh, Preethi; Vajravelu, Leela Kakithakara; Aravindhan, Vivekanandhan
A Corrigendum on Interleukin-13 as a potential biomarker in the management of pediatric asthma – a longitudinal study by Raju P, Sundar S, Suresh P, Vajravelu LK, Aravindhan V. Eur J Clin Exp Med. 2025;23(1):15–20. doi: 10.15584/ejcem.2025.1.3.
Interleukin-13 as a potential biomarker in the management of pediatric asthma – a longitudinal study
(Rzeszów University Press, 2025-03) Raju, Prasanna; Sundar, Subash; Suresh, Preethi; Vajravelu, Leela Kakithakara; Aravindhan, Vivekanandhan
Introduction and aim. Asthma is predominantly a Th2 type hypersensitive disorder, with interleukin (IL) 4 and IL-13 playing a pivotal roles. Interleukin 13 is one of several cytokines that cause persistent inflammation associated with asthma. The aim was to examine the relationship between the response to treatment in asthma and serum IL-13. Material and methods. This study, conducted at the SRM Medical College Hospital and Research Center, in Tamil Nadu, in volved 68 children aged 6 to 12 years of age diagnosed with asthma. The study included medical history, including age of onset of wheezing, history of allergic rhinitis/atopic dermatitis, food allergies, use of inhalational corticosteroids, hospital admissions, and family history. Spirometry was performed, and treatment with inhalational corticosteroids was started according to GINA guidelines. Blood was collected prior to and after 3 months of treatment. Results. A substantial positive correlation was observed between gender and IL-13 levels. An improvement in forced expirato ry volume in the first second (FEV1) was observed after treatment [(74.72% vs 95.05%) (p<0.0001)]. A negative correlation was discovered between IL-13 and FEV1. A statistical significance between IL-13 levels before and after treatment (p=0.005). Conclusion. Inhalational corticosteroids reduced serum IL-13 levels, indicating its role as a prognostic marker in pediatric asthma.